Sodium channel $\text{Na}_\text{V}1.9$ mutations associated with insensitivity to pain dampen neuronal excitability

Jianying Huang, … , Stephen G. Waxman, Alfred L. George Jr.

*J Clin Invest.* 2017;127(7):2805-2814. [https://doi.org/10.1172/JCI92373](https://doi.org/10.1172/JCI92373).

Voltage-gated sodium channel ($\text{Na}_\text{V}$) mutations cause genetic pain disorders that range from severe paroxysmal pain to a congenital inability to sense pain. Previous studies on $\text{Na}_\text{V}1.7$ and $\text{Na}_\text{V}1.8$ established clear relationships between perturbations in channel function and divergent clinical phenotypes. By contrast, studies of $\text{Na}_\text{V}1.9$ mutations have not revealed a clear relationship of channel dysfunction with the associated and contrasting clinical phenotypes. Here, we have elucidated the functional consequences of a $\text{Na}_\text{V}1.9$ mutation (L1302F) that is associated with insensitivity to pain. We investigated the effects of L1302F and a previously reported mutation (L811P) on neuronal excitability. In transfected heterologous cells, the L1302F mutation caused a large hyperpolarizing shift in the voltage-dependence of activation, leading to substantially enhanced overlap between activation and steady-state inactivation relationships. In transfected small rat dorsal root ganglion neurons, expression of L1302F and L811P evoked large depolarizations of the resting membrane potential and impaired action potential generation. Therefore, our findings implicate a cellular loss of function as the basis for impaired pain sensation. We further demonstrated that a U-shaped relationship between the resting potential and the neuronal action potential threshold explains why $\text{Na}_\text{V}1.9$ mutations that evoke small degrees of membrane depolarization cause hyperexcitability and familial episodic pain disorder or painful neuropathy, while mutations evoking larger membrane depolarizations cause hypoexcitability and insensitivity to pain.

Find the latest version:

[https://jci.me/92373/pdf](https://jci.me/92373/pdf)
Sodium channel $\text{Na}_1.9$ mutations associated with insensitivity to pain dampen neuronal excitability

Jianying Huang,1 Carlos G. Vanoye,2 Alison Cutts,3 Y. Paul Goldberg,3 Sulayman D. Dib-Hajj,1 Charles J. Cohen,3 Stephen G. Waxman,1 and Alfred L. George Jr.2

1Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine; and Rehabilitation Research Center, Veterans Administration Connecticut Healthcare System, West Haven, Connecticut, USA. 2Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 3Xenon Pharmaceuticals, Burnaby, British Columbia, Canada.

Introduction
Chronic pain is a prevalent and pernicious medical problem that represents an enormous public health burden. Understanding the molecular mechanisms and identifying critically important proteins involved in nociception may reveal novel therapeutic targets.

Strong evidence supports the contribution of 3 distinct voltage-gated sodium (Na) channels (Na1.7, Na1.8, and Na1.9), expressed predominantly in peripheral neurons including pain-signaling neurons, to normal and pathological pain perception (1–6). Whereas Na1.7 is a fast-gating and tetrodotoxin-sensitive (TTX-S) neuronal Na channel, Na1.8 and Na1.9 (also known as SNS and NaN, respectively) exhibit TTX resistance (TTX-R) (7–12). Na1.9 contributes to a persistent sodium current in small-diameter, nociceptive sensory neurons in dorsal root ganglia (DRGs) (13–15) and has been implicated in neuronal pain signaling triggered by inflammation (16–19). These physiological contributions of Na1.9 may stem from its unique biophysical properties. Specifically, Na1.9 exhibits voltage dependence of activation and inactivation that overlap near the resting membrane potential (RMP), slow inactivation gating kinetics, and a very large, persistent current (11, 20–24). These properties have been hypothesized to enable Na1.9 to regulate the threshold for excitability of peripheral nociceptive sensory neurons by modulating both the RMP and responses to sub-threshold stimuli (14, 15, 17, 23).

Voltage-gated sodium channels have been implicated in genetic pain disorders by the discovery of mutations in the genes encoding Na1.7, Na1.8, and Na1.9 (1–3, 5, 25, 26). Mutations in Na1.7 and Na1.8 have been extensively analyzed, and a clear genotype-phenotype correlation has emerged (2, 27, 28). For Na1.7, mutations producing gain-of-function biophysical changes at the channel level are associated with disorders of paroxysmal pain (inherited erythromelalgia, paroxysmal extreme pain disorder), whereas those with loss-of-function properties are associated with congenital insensitivity to pain (CIP). Likewise, for Na1.8, gain-of-function mutations have been identified in subjects with painful peripheral neuropathy. Further, gain-of-function Na1.7 mutations promote hyperexcitability of DRG neurons in vitro, whereas global knockout of this gene in mice produces the opposite phenotype of insensitivity to pain, with reduced action potential firing in DRG neurons (29), consistent with the increase in threshold of DRG neurons produced by blockade of Na1.7 (30). This collective work on Na1.7 and Na1.8 has established a clear relationship between gain of function at the channel level and severe pain, and channel loss of function and insensitivity to pain, for these 2 channel subtypes.

By contrast, no clear relationship between channel dysfunction and clinical phenotype has yet emerged from early work on Na1.9 mutations. Mutations of Na1.9 have recently been associated with

Conflict of Interest: The authors have declared that no conflict of interest exists.

either loss of pain perception (26, 31, 32) or the opposite phenotypes of familial episodic pain and painful peripheral neuropathy (33–37). All mutant Na\(_{\text{v}}\)1.9 channels for which biophysical data are available show hyperpolarizing shifts in channel activation, which is consistent with a gain of function at the channel level, despite the contrasting nature of the associated clinical phenotypes. The physiological basis for this paradox has not been resolved.

In this study, we elucidated the functional consequences of the second Na\(_{\text{v}}\)1.9 mutation (L1302F) associated with insensitivity to pain and investigated the impact of the 2 known Na\(_{\text{v}}\)1.9 mutations associated with this condition on the excitability of nociceptive neurons. Our observations demonstrate how these Na\(_{\text{v}}\)1.9 mutations, which produce a severe gain of function at the channel level, can cause reduced excitability of dorsal root ganglion neurons, consistent with a loss of pain sensibility at the clinical level.

Results

Phenotype and genetics of a proband with insensitivity to pain. We studied a previously described French woman with insensitivity to pain (38). Briefly, both the proband and her mother (Figure 1A) suffered multiple painless orthopedic injuries during childhood including several painless fractures of the lower extremities. Between the ages of 4 and 13 years, the proband suffered a total of 11 fractures, including multiple fractures to both the right and left tibiae. There was radiographic evidence of advanced destruction of the calcaneum and talus. The affected subjects did not perceive a noxious stimulus such as pin-prick as painful and were unable to distinguish a sharp from a blunt object when blinded. Light touch, temperature, and vibration sensations were normal for both affected individuals. Motor nerve conduction velocities were normal for both patients, and nerve fibers were deemed normal upon examination by light and electron microscopy. Motor milestones as well as cognitive and neurological development were normal. The proband reported a normal sense of smell, unlike CIP patients with Na\(_{\text{v}}\)1.7 mutations, who have anosmia (39, 40). The proband reported severe pruritus since childhood, resulting in painless excoriating lesions of the thorax, ears, and nose from scratching her wounds. She had surgery at age 13 for nasal septum prostheses due to repeated nasal trauma and subsequent deformity. Although the original report on this subject (38) did not document autonomic disturbances, the proband subsequently reported a history of persistent diarrhea of unknown cause as well as episodic abdominal pain beginning in childhood and persisting into adulthood. Sweating was reported as normal.

Targeted sequence analysis of Na\(_{\text{v}}\)1.9, Na\(_{\text{v}}\)1.8, and Na\(_{\text{v}}\)1.9 in the proband identified a heterozygous Na\(_{\text{v}}\)1.9 coding variant (c.3904C>T, p.Leu1302Phe [L1302F]) (Figure 1B), which was recently reported in an unrelated family with insensitivity to pain (32). The variant affects a highly conserved residue in the S6 segment of domain III and is absent in the Genome Aggregation Database (http://gnomad.broadinstitute.org/). Other family members, including the unaffected maternal grandmother and 2 unaffected maternal aunts, did not harbor the L1302F variant. We
The L1302F mutation has a significantly hyperpolarized (−26.9 mV shift) voltage dependence of activation (Table 1) and a significantly steeper slope (Table 1) compared with WT channels (Figure 3A). By contrast, the voltage dependence of inactivation following a 300-ms prepulse was not different between WT and L1302F channels (Figure 3B and Table 1), but the slope factor was significantly different (Table 1). The steady-state inactivation and conductance voltage (activation) curves for WT sodium currents intersected near −50 mV, while those for L1302F intersected around −70 mV (Figure 3C). The hyperpolarized shift in activation voltage dependence, without a concomitant shift in the voltage dependence of inactivation observed for L1302F, creates an expanded range of membrane potentials at which channels will be conducting (window current). The physiological impact of this finding would be predicted to be the potentiation of channel activity at or near the resting potential or nociceptive DRG neurons.

**Effects of mutant Na1.9 on DRG neuron excitability.** To assess the effect of Na1.9 mutations on DRG neuron excitability, we performed current-clamp recordings in small (<30 μm) rat DRG neurons electroporated with WT or L1302F channels. Na1.9 is known to contribute to a depolarizing effect on the resting membrane potential (RMP) (23, 41), and we expected that the enhanced window current of L1302F would potentiate this effect. Consistent with this expectation, we observed that expression of L1302F evoked a marked depolarization of the average RMP by 11.5 mV as compared with WT channel expression in small DRG neurons (Figure 4A and Table 2). All neurons expressing WT Na1.9 fired action potentials, with an average current threshold of 290 ± 38 pA (Figure 4B and Table 2). A representative action potential from a neuron expressing WT Na1.9 channels evoked when the current injection reached 280 pA is shown in Figure 4B. The RMP for this neuron was −57.2 mV. By contrast, 4 of 32 (13%) neurons expressing L1302F were unable to fire action potentials in response to stimuli applied at their native resting potentials. All nonfiring L1302F-expressing cells exhibited markedly depolarized RMP values (Figure 4A, solid orange circles).

Because we expected that the depolarized RMP would contribute to the effect of the mutant channel on DRG neuron excitability, we imposed a relatively normal membrane potential in cells expressing these mutant channels by injecting a hyperpolarizing current to achieve a holding potential of −60 mV. All 4 of these cells regained excitability when held at −60 mV and either fired action potentials, with an average current threshold of 290 ± 38 pA (Figure 4A and Table 2). All neurons expressing WT Na1.9 fired action potentials, with an average current threshold of 290 ± 38 pA when held at −60 mV (Figure 4D).

We observed similar phenomena in neurons transfected with L811P, which was previously associated with insensitivity to pain (26). Small DRG neurons expressing L811P exhibited an 8.2-mV depolarized RMP, a smaller effect than was observed for

<table>
<thead>
<tr>
<th>Table 1. Functional properties of WT and mutant human Na1.9 channels</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Peak current density</strong> (pA/pF)</td>
</tr>
<tr>
<td>---------------------------------</td>
</tr>
<tr>
<td>WT</td>
</tr>
<tr>
<td>L1302F</td>
</tr>
</tbody>
</table>

*P < 0.05 and *P < 0.001, by t test compared with WT values.
channels, including NaV1.8, which contributes substantially to the activity of L1302F or L811P caused inactivation of voltage-gated sodium channels. We previously demonstrated that the action potential amplitude was attenuated significantly in cells expressing L1302F and L811P at their native resting potentials (Table 2) but was rescued by holding cells at –60 mV (Table 3). The magnitude of the reduction in action potential amplitude by L1302F (20%) was greater than that for L811P (8.5%), paralleling the larger RMP depolarization in cells expressing L1302F (11.5 mV for L1302F versus 8.2 mV for L811P; Table 2).

Because it is difficult to measure the responses to injected current in spontaneously firing neurons, we excluded them from the analysis of RMP, input resistance, and amplitude of action potential. We did not observe a difference in the percentage of cells expressing L1302F or L811P that fired spontaneously at the native RMP as compared with cells expressing WT channels (Table 2). However, cells expressing L1302F or L811P showed a significantly higher proportion of spontaneously firing cells than did WT cells when using a holding potential of –60 mV (Table 3, and Figure 5B).

These observations are consistent with the conclusion that, at the channel level, mutations confer a gain of function, which evokes neuronal hyperexcitability at a physiological RMP.

Input resistance was significantly smaller in DRG neurons expressing L1302F than in cells expressing WT channels at both the native RMP and when held at –60 mV (Tables 2 and 3). Neuronal hyperexcitability underlies the reduced action potential amplitude is due to inactivated NaV channels, we observed that the action potential amplitude was attenuated significantly in cells expressing L1302F and L811P.

Table 2. Electrophysiological properties of small DRG neurons expressing WT or mutant NaV1.9 measured at native resting membrane potentials

<table>
<thead>
<tr>
<th></th>
<th>Resting membrane potential (mV)</th>
<th>Nonfiring cells (%)</th>
<th>Input resistance (MΩ)</th>
<th>Current threshold (pA)</th>
<th>AP amplitude (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comparison of WT and L1302F</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>–52.7 ± 0.89 (n = 32)</td>
<td>0/32 (0%)</td>
<td>535 ± 54 (n = 32)</td>
<td>290 ± 38 (n = 32)</td>
<td>107 ± 19 (n = 32)</td>
</tr>
<tr>
<td>L1302F</td>
<td>–41.2 ± 1.5 (n = 32)</td>
<td>4/32 (13%)</td>
<td>353 ± 39 (n = 28)</td>
<td>243 ± 37 (n = 28)</td>
<td>85.7 ± 34 (n = 28)</td>
</tr>
<tr>
<td><strong>Comparison of WT and L811P</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>–53.4 ± 0.57 (n = 51)</td>
<td>0/51 (0%)</td>
<td>555 ± 37 (n = 51)</td>
<td>236 ± 27 (n = 51)</td>
<td>106 ± 15 (n = 51)</td>
</tr>
<tr>
<td>L811P</td>
<td>–45.2 ± 1.4 (n = 46)</td>
<td>4/46 (8.7%)</td>
<td>465 ± 35 (n = 42)</td>
<td>188 ± 26 (n = 42)</td>
<td>97 ± 2.3 (n = 42)</td>
</tr>
</tbody>
</table>

*p < 0.05, by z test compared with WT values; **p < 0.01 and ***p < 0.001, by t test compared with WT values. AP, action potential.
RMP depolarization in small DRG neurons. (A) Scatter-plot of the RMP recording from neurons expressing either WT or L1302F NaV1.9 channels. *** * P < 0.001, by t test. Solid orange circles indicate cells that did not fire all-or-none action potentials in response to external stimuli at their native resting potentials (–24.2 mV, –26.6 mV, –31.9 mV, and –32.7 mV, respectively) but regained excitability when held at –60 mV. (B) Representative action potential in a small DRG neuron overexpressing WT channels evoked when the current injection reached 280 pA. The native resting potential for this neuron was –57.2 mV. (C) Small DRG neuron with a RMP of –26.6 mV (indicated by an arrow in panel A) did not fire action potentials in response to 200-ms current injections from 0 to 500 pA in 100-pA increments. When held at –60 mV, the same neuron as that depicted in C produced subthreshold depolarizations in responses to 30-pA and 35-pA current injections and generated action potentials with a threshold current of 40 pA. (E) Scatter-plot of the RMP in neurons overexpressing either WT or L811P NaV1.9 channels. *** * P < 0.001, by t test. Four cells indicated by solid purple diamonds did not fire action potentials in response to external stimuli at their native resting potentials (–20.5 mV, –22.7 mV, –27.2 mV, and –32.9 mV, respectively), but fired spontaneously when held at –60 mV (illustrated in panel F). The cell indicated by the arrow had a RMP of –32.9 mV. (F) Representative spontaneous firing from a holding potential of –60 mV recorded from the cell marked by an arrow in E.

Impact of RMP depolarization on current threshold and action potential amplitude. Expression of either L1302F- or L811P-mutant channels produced large RMP depolarizations in small DRG neurons. To model the effect of this depolarization on neuron excitability, we examined nontransfected adult rat DRG neurons within 8 hours of isolation using whole-cell current-clamp recording. Inward currents were injected to clamp the membrane potential at a series of voltages from –60 mV to –30 mV in 2.5-mV increments. This experiment demonstrated that the current threshold for action potential generation falls in direct relationship to the extent of membrane depolarization until a critical point, at which further depolarization requires larger stimuli to initiate a response, is reached (Figure 6A). This U-shaped curve is similar to the relationship between current threshold and resting potential predicted from studies in which the membrane potential was modulated by injections of hyperpolarizing and depolarizing current more centrally along the somatosensory pathway in rat dorsal column axons (44).

This relationship provides an explanation for why large depolarizations caused by expression of L1302F (11.5 mV) or L811P (8.2 mV) are associated with hypoexcitability, whereas lesser degrees of membrane depolarization, which are evoked by other NaV1.9 mutations associated with familial episodic pain disorder or pain-
ful neuropathy, cause neuronal hyperexcitability. The representative action potential traces recorded from nontransfected DRG neurons at different clamping voltages (−60 mV, −52.5 mV, −42.5 mV, and −40 mV) shown in the bottom panel of Figure 6A further validate this conclusion. The relationship between action potential amplitude and the extent of RMP depolarization is best fit by a Boltzmann function having a midpoint voltage (−38.7 ± 2.3 mV; Figure 6B) that is close to the midpoint voltage for fast inactivation of Na\textsubscript{a}1.8, which contributes a major component of the inward current underlying the action potential upstroke, and is consistent with the midpoint voltage (−37 mV) determined previously for TTX-R current in DRG neurons (43).

**Discussion**

Syndromes of insensitivity to pain have been associated with mutations of 2 voltage-gated sodium channels, Na\textsubscript{a}1.7 and Na\textsubscript{a}1.9. In the case of Na\textsubscript{a}1.7, a sodium channel that sets the gain on nociceptive DRG neurons (30, 45, 46), the congenital inability to sense pain is associated with recessive mutations that produce loss of function at the channel level (39, 47, 48). By contrast, dominant Na\textsubscript{a}1.7 mutations that produce gain-of-function changes, including a hyperpolarizing shift in the voltage dependence of activation at the channel level, are associated with genetic disorders featuring increased pain sensation (49–52). Unlike the distinct relationships between channel defects and clinical phenotypes for Na\textsubscript{a}1.7, dominant mutations that produce gain of function in Na\textsubscript{a}1.9 at the channel level have been associated with syndromes characterized by both insensitivity to pain (26, 31) and severe pain (6, 33, 34, 36). The mechanistic link between Na\textsubscript{a}1.9 gain of function and insensitivity to pain has been elusive.

The results of our functional profiling provide a mechanistic explanation for a loss of pain sensibility in these patients. Specifically, our voltage-clamp studies revealed a large hyperpolarizing shift in the voltage dependence of activation for L1302F (−26.9 mV) that was qualitatively similar to the results reported for the L811P mutation (26). This biophysical effect causes a larger window of overlap between the voltage dependence of activation and steady-state inactivation (Figure 3C), and this phenomenon is expected to promote large depolarizing current near the RMP in DRG neurons carrying these mutations. Consistent with this prediction, we observed large depolarizations in the average resting potential (11.5 mV for L1302F and 8.2 mV for L811P) in DRG neurons transfected with either mutation, with resulting impairments in action potential generation.

To examine the effect of this depolarization on excitability, we assessed the effect of holding potential on current threshold in non-

---

**Table 3. Electrophysiological properties of small DRG neurons expressing WT or mutant Na\textsubscript{a}1.9 (holding potential of −60 mV)**

<table>
<thead>
<tr>
<th>Spont. firing cells (%)</th>
<th>Input resistance (MΩ)</th>
<th>Current threshold excl. spont. firing cells (pA)</th>
<th>Current threshold incl. spont. firing cells* (pA)</th>
<th>AP amplitude (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WT</strong></td>
<td>0/24 (0%)</td>
<td>519 ± 55 (n = 19)</td>
<td>284 ± 44 (n = 24)</td>
<td>116 ± 1.9 (n = 24)</td>
</tr>
<tr>
<td><strong>L1302F</strong></td>
<td>7/30 (23%)</td>
<td>374 ± 30 (n = 21)</td>
<td>139 ± 31 (n = 23)</td>
<td>106 ± 2.6 (n = 30)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>108 ± 2.7 (n = 23)</td>
</tr>
<tr>
<td><strong>Comparison of WT and L1302F</strong></td>
<td></td>
<td></td>
<td></td>
<td>116 ± 1.9 (n = 24)</td>
</tr>
</tbody>
</table>

*Current threshold for spontaneously firing cells was assigned a value of 0 pA; \(P < 0.05\) and \(P < 0.001\), by z test compared with WT values; \(P < 0.05\), \(P < 0.01\), and \(P < 0.001\), by t test compared with WT values. incl., including; excl., excluding; Spont., spontaneously.

---

**Figure 5. Effects of mutant channels on action potential properties.**

(A) Representative recordings demonstrating that expression of L1302F (orange trace) and L811P (purple trace) was associated with a depolarized RMP and an attenuated action potential overshoot as compared with cells expressing WT channels (blue trace). (B) Proportions of spontaneously firing cells. Colors represent the percentage of spontaneously firing cells for WT (blue), L1302F (orange), and L811P (purple) when studied at the native RMP or when using a holding potential of −60 mV. The plotted data sets for the native RMP were L1302F: 18 of 50 cells (36%) versus WT: 12 of 44 cells (27%), \(P = 0.35\), by z test, and L811P: 18 of 64 cells (28%) versus WT: 9 of 60 cells (15%), \(P = 0.079\), by z test. When cells were held at −60 mV, 23% of cells expressing L1302F (7 of 30) as opposed to 0% of cells expressing WT fired spontaneously (\(P = 0.012\), by z test), whereas 50% of cells expressing L811P (30 of 60) fired spontaneously as compared with 3.6% (2 of 56) of cells expressing WT (**\(P < 0.0001\), by z test).
transfected adult rat DRG neurons. This experiment demonstrated that the current threshold for action potential generation decreases gradually with membrane depolarization until a critical point, at which further depolarization requires larger stimuli to initiate a response, is reached. Notably, when we injected current into nontransfected cells to produce membrane depolarizations similar to those caused by expression of L1302F (+11.5 mV) or L811P (+8.2 mV), we observed a reduced ability to fire action potentials. These findings are in contrast to our previous observations that a 4- to 6-mV depolarization in the resting potential of DRG neurons associated with multiple NaV1.9 mutations results in neuronal hyperexcitability and paroxysmal pain disorders (27, 34, 53–55). These divergent observations regarding the effects of mutations on neuronal excitability are explained by the U-shaped relationship between resting potential and action potential amplitude (Figure 6A), which demonstrates hyperexcitability of neurons with a severely depolarized RMP, with some cells displaying a RMP more depolarized than –35 mV (Figure 4E), a voltage domain where there is clear hypoexcitability of DRG neurons. We would also note that mutant channel behaviors reported in the earlier study differ between human NaV1.9-L811P and mouse NaV1.9-L799P, which is not surprising, given the poor conservation of these orthologous proteins (e.g., 73% amino acid identity) relative to other mammalian sodium channels. Although both human and mouse mutations evoke a similar hyperpolarized activation voltage dependence, there were notable differences in the time course of inactivation, sodium current density, and voltage dependence of inactivation (26), all of which confound direct comparisons and diminish the reliability of extrapolating across species.

Some parallels can be drawn between the divergent cellular effects of NaV1.9 gain-of-function mutations and those of the skeletal muscle channel NaV1.4, mutations, which are associated with genetic disorders of muscle contraction (57, 58). Gain-of-function NaV1.4 mutations predominantly cause myotonia or periodic paralysis, symptoms that represent either enhanced or diminished sarcolemmal excitability, respectively. This spectrum of pathophysiological effects has been attributed to specific mechanisms of channel dysfunction and the manner by which dysfunctional channels affect the resting potential. Mutations that impair fast inactivation typical of myotonic disorders promote hyperexcitability by increasing sodium channel availability and by prolonging the muscle action potential, which promotes greater t-tubular potassium accumulation and a greater probability of after-depolarizations. By contrast, an enhanced persistent activation values ($V_{1/2}$) of –73 and –37 mV, matching the $V_{1/2}$ values for steady-state fast inactivation of TTX-S (NaV1.7) and TTX-R (NaV1.8) sodium channels, respectively, and pointing to inactivation of these channels as critical for action potential amplitude. Consistent with these earlier findings, we observed here that the action potential amplitude was attenuated significantly ($P < 0.001$, Table 2) in DRG neurons expressing L1302F and L811P at their native resting potentials, but the ability to fire full, overshoot- ing action potentials was restored when membrane potentials in these neurons were set to –60 mV, reversing NaV inactivation.

Impaired excitability of nociceptor neurons was also observed in mice with an engineered murine NaV1.9 mutation (L799P) analogous to human NaV1.9-L811P, but a different interpretation of the mechanisms responsible for this effect was offered (26). Specifically, Leipold and colleagues argued for a conduction block secondary to inactivation of NaV1.7, NaV1.8, and neuronal calcium channels as the central basis for impaired nociception (26). By contrast, our data support a primary loss of neuronal excitability as a direct consequence of a massively depolarized RMP, with some cells displaying a RMP more depolarized than –35 mV (Figure 4E), a voltage domain where there is clear hypoexcitability of DRG neurons. We would also note that mutant channel behaviors reported in the earlier study differ between human NaV1.9-L811P and mouse NaV1.9-L799P, which is not surprising, given the poor conservation of these orthologous proteins (e.g., 73% amino acid identity) relative to other mammalian sodium channels. Although both human and mouse mutations evoke a similar hyperpolarized activation voltage dependence, there were notable differences in the time course of inactivation, sodium current density, and voltage dependence of inactivation (26), all of which confound direct comparisons and diminish the reliability of extrapolating across species.

Some parallels can be drawn between the divergent cellular effects of NaV1.9 gain-of-function mutations and those of the skeletal muscle channel NaV1.4, mutations, which are associated with genetic disorders of muscle contraction (57, 58). Gain-of-function NaV1.4 mutations predominantly cause myotonia or periodic paralysis, symptoms that represent either enhanced or diminished sarcolemmal excitability, respectively. This spectrum of pathophysiological effects has been attributed to specific mechanisms of channel dysfunction and the manner by which dysfunctional channels affect the resting potential. Mutations that impair fast inactivation typical of myotonic disorders promote hyperexcitability by increasing sodium channel availability and by prolonging the muscle action potential, which promotes greater t-tubular potassium accumulation and a greater probability of after-depolarizations. By contrast, an enhanced persistent
sodium current (59, 60) or an anomalous gating pore current (61, 62) typical of mutations associated with either hyperkalemic or hypokalemic periodic paralysis, respectively, causes sustained depolarization of the resting potential and inexcitability owing to inactivation of WT sodium channels. The cellular effects of Na<sub>V1.9</sub> mutations associated with insensitivity to pain are most reminiscent of the behavior of Na<sub>V1.4</sub> in hypokalemic periodic paralysis, in that abnormal sodium conductance renders the membrane depolarized and inexcitable.

In conclusion, we determined that large hyperpolarizing shifts in the voltage dependence of activation in mutant Na<sub>V1.9</sub> channels associated with insensitivity to pain evoke a degree of membrane depolarization that renders DRG neurons hypoexcitable, probably because of inactivation of other peripheral nerve sodium channels (including Na<sub>V1.8</sub>). Thus, our observations provide a mechanistic explanation for loss of pain sensibility associated with Na<sub>V1.9</sub> mutations that exhibit severe gain of function at the channel level.

Methods

**Study subject and molecular genetics.** A French proband with insensitivity to pain and her family were recruited as part of a larger study to investigate the molecular basis of loss of sensitivity to pain. At age 33, the proband was enrolled in our study, at which time an updated medical history was collected from the patient’s self-reports. Genetic studies included Sanger sequencing of SCN9A (NaV1.7), SCN10A (Na<sub>V1.8</sub>), and SCN11A (Na<sub>V1.9</sub>). Subsequently, whole-exome sequencing was performed using the SureSelect V4 Capture Reagent (Agilent Technologies), followed by 80× on-target sequencing using a HiSeq 2000 Sequencer (Illumina).

**Plasmids and cell transfection.** The L811P and L1302F mutations were introduced into full-length human Na<sub>V1.9</sub> cDNA (GenBank accession number NP_0554858.2) including a C-terminal triple FLAG epitope as previously described (22). All recombinant cDNAs were sequenced in their entirety to confirm the presence of the intended modifications and the absence of unwanted mutations.

Heterologous expression experiments were conducted using ND7/23 cells (Sigma-Aldrich) grown at 37°C with 5% CO<sub>2</sub> in DMEM supplemented with 10% FBS (Atlanta Biologicals), 2 mM L-glutamine, and penicillin/streptomycin (50 units/ml and 50 μg/ml, respectively). Unless otherwise stated, all tissue culture media were obtained from Life Technologies (Thermo Fisher Scientific).

Stable expression of mutant Na<sub>V1.9</sub> channels in ND7/23 cells (Sigma-Aldrich) was achieved using the piggyBac transposon system as previously described (63, 64) using a transposon vector containing a puromycin resistance gene (pB-Na<sub>V1.9</sub>_mut-3xFLAG-PuroR). ND7/23 cells were cotransfected with a NaV1.9 plasmid and pCMV-hyPBase encoding a hyperactive version of the piggyBac transposase (65) using FUGENE-6 (Roche Applied Science). Stable Na<sub>V1.9</sub>-expressing cells were selected with puromycin (3 μg/ml; Gibco, Invitrogen, Thermo Fisher Scientific), and individual cell colonies were isolated by limited dilution. The ND7/23 cell line stably expressing human WT Na<sub>V1.9</sub> was previously reported (22).

**Voltage-clamp electrophysiology.** Cells stably expressing Na<sub>V1.9</sub> were incubated at 28°C with 5% CO<sub>2</sub> for approximately 24 hours before their use in electrophysiology experiments. Cells were dissociated by trituration, resuspended in supplemented DMEM medium (without puromycin), plated on glass coverslips, and allowed to recover for approximately 2 hours (1 h at 37°C, and then at 28°C) before electrophysiology experiments.

Sodium currents were recorded at room temperature in the whole-cell configuration of the patch-clamp technique (66) using an Axopatch 200B series amplifier (Molecular Devices). Whole-cell currents were acquired at 20 kHz and filtered at 5 kHz. Pulse generation and data collection were done with Clampex 9.2 (Molecular Devices). Bath solution contained 145 mM NaCl, 4 mM KCl, 1.8 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM HEPES, pH 7.35, and 310 mM mOsm/kg. TTX (150 nM) was present in the bath to block endogenous sodium currents. The composition of the pipette solution was as follows: 10 mM NaF, 110 mM CsF, 20 mM CsCl, 2 mM EGTA, 10 mM HEPES, pH 7.35, and 310 mOsm/kg. Osmolality and pH values were adjusted with sucrose and NaOH, respectively. Patch pipettes were pulled from thin-wall borosilicate glass (Warner Instruments) with a multistage P-97 Flaming-Brown Micropipette Puller (Sutter Instruments) and fire-polished with a Micro Forge MF 830 (Narashige). Pipette resistance was approximately 2 MΩ with standard recording solutions. Agar (2%) bridges containing bath solution served as reference electrodes.

Cells were allowed to equilibrate for 10 minutes in bath solution before obtaining seals. Peak currents were measured with pulses between –100 and +40 mV (10 s at the holding potential between pulses) from a holding potential of –120 mV. The peak current was normalized for cell capacitance and plotted against voltage to generate peak current density–voltage relationships. Whole-cell conductance was calculated from the peak current amplitude using the formula: $G_{\text{Na}} = I_{\text{Na}} / V - E_{\text{rev}}$, where $G_{\text{Na}}$ is sodium conductance, $I_{\text{Na}}$ is sodium current measured at test potential $V$, $E_{\text{rev}}$ is the estimated Na+ reversal potential, and then normalized to the maximal conductance recorded between –100 and 0 mV.

The voltage dependence of activation was calculated by fitting the normalized G-V curves with a Boltzmann function. The voltage dependence of channel availability was assessed following a 300-msec prepulse to various potentials and normalizing to the current measured following a pulse to –40 mV (membrane held for 20 s at the holding potential between pulses). The normalized G-V curves were fit with the Boltzmann function: $G = 1/(1 + \exp[V - V_{1/2}] / k)$ to determine the $V_{1/2}$ and slope factor (k).

**Isolation and transfection of primary sensory neurons.** DRGs from 4- to 6-week-old female and male Sprague-Dawley rats were harvested and dissociated as described previously (67). Briefly, DRG neurons were dissociated with a 20-minute incubation in 1.5 mg/ml collagenase A (Roche) and 0.6 mM EDTA, followed by an 18-minute incubation in 1.5 mg/ml collagenase D (Roche), 0.6 mM EDTA, and 30 U/ml papain (Worthington Biochemical Corp.). DRGs were then centrifuged and triturated in 0.5 ml of media containing 1.5 mg/ml BSA (low endotoxin) and 1.5 mg/ml trypsin inhibitor (Sigma-Aldrich). After trituration, 2 ml of DRG media were added to the cell suspension, which was filtered through a 70-μm nylon mesh cell strainer (BD Technologies). The mesh was washed twice with 2 ml of DRG media. The cells were then cotransfected with WT or mutant human Na<sub>V1.9</sub> plasmids and a plasmid encoding GFP using a Nucleofector IIS (Lonza) and an Amaxa Basic Neuron SCN Nucleofector Kit (VSP1-1003). Briefly, the cell suspension was centrifuged (100 × g for 5 min), and the cell pellet was resuspended in 20 μl Nucleofector solution, mixed with 2 μg WT, L1302F, or L811P Na<sub>V1.9</sub> plasmid plus 0.2 μg GFP plasmid, and transfected using Nucleofector IIS and protocol SCN-BNP 6. After transfection, cells were allowed to recover in calcium-free DMEM, fed with DRG media supplemented with nerve growth.
factor (50 ng/ml) and glial cell line-derived neurotrophic factor (50 ng/ml), and maintained at 37°C with 5% CO2, for 40 to 55 hours before current-clamp recording. Recordings were obtained from nontransfected adult rat DRG neurons within 8 hours of isolation.

**Current-clamp electrophysiology.** The pipette solution contained the following: 140 mM KCl, 3 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 10 mM dextrose, pH 7.30, with NaOH (adjusted to 320 mOsm with sucrose). The bath solution contained the following: 140 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, and 10 mM dextrose, pH 7.30, with NaOH (adjusted to 320 mOsm with sucrose). A whole-cell configuration was obtained in voltage-clamp mode before proceeding to the current-clamp recording mode. The electrophysiologist was blinded with respect to exogenous sodium channel expression in DRG neurons (either WT or mutant Na1.9) until after data analysis. Small DRG neurons with a diameter of less than 30 μm and green fluorescence were selected for recording. A stable (<10% variation) RMP for 30 seconds and the presence of endogenous Na1.8 currents (>1 nA) evaluated by holding neurons at –50 mV were used as additional criteria for inclusion. Input resistance was determined by the slope of a linear fit to hyperpolarizing responses to current steps from –5 pA to –40 pA in 5-pA increments. The minimum current injection required to achieve firing of a single action potential (designated as the current threshold) was determined at the first action potential elicited by a series of depolarizing current injections (200 ms) applied in 5-pA increments. Action potential amplitude was measured by the spike height from the peak to the RMP. Spontaneously firing cells were excluded from the analysis of RMP, input resistance, and action potential amplitude.

**Statistics.** Voltage-clamp data were analyzed and plotted using a combination of Clampfit 9.2 (Molecular Devices), SigmaPlot 12.5 (Systat Software), and Origin 7.0 (OriginLab). Statistical analyses were carried out using the statistical analysis option in SigmaPlot. Current-clamp data were analyzed using Fitmaster (HEKA Elektronik) and Origin (Microcal Software) software. Percentages of nonfiring cells and spontaneously firing cells were compared using the χ2 test. Unless otherwise noted, statistical significance was determined using an independent 2-tailed t test. All electrophysiology data are presented as the mean ± SEM, and error bars in the figures represent the SEM. The number of cells (n) used for each experimental condition is indicated in the figures, figure legends, or tables. A P value of less than 0.05 was considered significant.

**Study approval.** The human study was approved by an independent ethics review board (protocol CIP-SEQ-001; Quorum Review, Inc., Seattle, WA, USA), and the proband provided written informed consent for participation and publication of the findings. Animal use was approved by the IACUC of the Veterans Administration West Haven Hospital.

**Author contributions**

JH, CGV, AC, and YPG performed experiments, collected and analyzed data, and contributed to the writing of the manuscript; SDDH, CJG, SGW, and ALG designed the study, evaluated results, and wrote the manuscript.

**Acknowledgments**

The authors thank Dayna Nevay, Emma Leach, Chris Radomski, and Julie MacFarlane (Xenon Pharmaceuticals, Inc.) for help with phenotype ascertainment and molecular genetics and Shujun Liu, Fadia Dib-Hajj, and Palak Shah (Yale University) for their technical assistance with this project. This work was supported by grants from the NIH (NS032387, to ALG); the Northwestern Medicine Catalyst Fund (to CGV and ALG); the Rehabilitation Research and Development Service and Medical Research Service of the Department of Veterans Affairs (to SGW); and the Erythromelalgia Association (to SGW). The Center for Neuroscience and Regeneration Research is a collaboration of the Paralyzed Veterans of America with Yale University.

 Address correspondence to: Alfred L. George Jr., Department of Pharmacology, Northwestern University Feinberg School of Medicine, 320 East Superior Street, Chicago, Illinois 60611, USA. Phone: 312.503.4893; E-mail: al.george@northwestern.edu. Or to: Stephen G. Waxman, Neurorehabilitation Research Center, Veterans Affairs Hospital, 950 Campbell Ave, Building 34, West Haven, Connecticut 06516, USA. Phone: 203.668.1141; Email: stephen.waxman@yale.edu.